Law360, San Francisco (May 19, 2011, 1:51 PM EDT) -- Schering Corp. on Tuesday won the dismissal of an inequitable conduct counterclaim by Mylan Pharmaceuticals Inc. in a ruling in Schering's lawsuit accusing the generic-drug maker of infringing its patents on cholesterol drug Vytorin. (A previous version of this article incorrectly stated that a ruling had been made on Mylan's antitrust counterclaims.)
U.S. District Judge Jose L. Linares granted Schering's bid to throw out Mylan's claim that it committed inequitable conduct by failing to disclose information to the U.S. Patent and Trademark Office.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.